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Abstract. The objective of this study were to assess the im-
pact of a quality assurance effort on the door-to-needle
time and the choice of thrombolytic agent for the manage-
ment of acute myocardial infarction in the emergency de-
partment. The study design involved a prospective collec-
tion of data on a series of consecutive patients who
received a thrombolytic agent for a presumed acute my-
ocardial infarction. The study was carried out in the emer-
gency department of a major university urban tertiary care
center. A total of 349 patients were studied from
September 1989 to March 1994. The quality assurance pro-
gram began in 1989 and included chart review of all pa-
tients receiving thrombolytic therapy, with special atten-
tion to all patients with door-to-needle times .60 minutes
to identify causes for delay. Feedback was directed to phar-
macy, nursing, and physician staff. Biannual reports were
distributed throughout the hospital and the emergency de-
partment. Nursing-specific feedback led to the develop-
ment of protocols for all aspects of the delivery of throm-
bolytic agents. The choice of thrombolytic agent was not
dictated by the protocol, but the physician staff was con-
tinuously updated on the results of the latest clinical trials
comparing one thrombolytic agent with another. The mean
age was 58 years for men and 67 years for women in this co-
hort consisting of 78% men and 22% women. Thirty-seven
percent of the myocardial infarctions were in an anterior
location and 56% were in an inferior location. The median
duration of chest pain before presentation to the emer-
gency department was 120 minutes. Hospital mortality was
3%. Median door-to-needle time fell from 46 (1989–1991)
to 36 (1992–1994) minutes, P , 0.01. The percentage of pa-
tients with a door-to-needle time .60 minutes decreased
from 35% (1989–1991) to 16% (1992–1994) minutes, P ,
0.0001. Corresponding with the ISIS-3 report, there was a
significant increase in the proportion of patients receiving
streptokinase over the first 3 years of the study (P ,
0.0001), which changed to a trend toward increased uti-
lization of tissue plasminogen activator with the GUSTO re-
port in the final 6 months of the study. In conclusion, a
quality assurance program led to a significant reduction in
the door-to-needle time, and recent megatrials were found
to in_uence the choice of thrombolytic agent used.
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Intravenous thrombolytic agents signi~cantly lower
mortality after an acute myocardial infarction when
given within 12 hours of the onset of chest pain [1–3].
Recent studies have shown that early delivery of the
agent, especially within the ~rst 4 hours of symptoms,
is associated with a greater mortality bene~t.
However, in most centers there is a substantial delay
from presentation to actual drug infusion (door-to-nee-
dle time). The average door-to-needle time has been
reported as 45–90 minutes [4–10]. Analysis of factors
leading to delays in initiating therapy have suggested
that a substantial portion of the total delay occurs after
patients arrive at the hospital. For instance, in an
analysis of the TIMI 2 trial, in-hospital delay ac-
counted for 59% of the total time from the onset of
symptoms of infarction to the initiation of tissue plas-
minogen activator (t-PA) therapy [4]. It has been said
that reducing the in-hospital delay in the administra-
tion of thrombolytic therapy represents the best op-
portunity to further maximize the present-day treat-
ment of myocardial infarction [4].
A recent multicenter prospective trial [11] exam-
ined the hospital attributes that correlated with a
more rapid door-to-needle time. The study demon-
strated that urban location, teaching hospital status,
and higher case volumes were each associated with
more rapid thrombolytic administration. We hypothe-
sized that if a relatively simple and inexpensive qual-
ity assurance effort could reduce the door-to-needle
time of our center, then such a program might yield
even greater ef~ciencies in other centers.
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In addition to documenting the importance of
ef~cient delivery of thrombolytic agents to acute my-
ocardial infarction patients, recent megatrials have
also in_uenced the choice of thrombolytic agents.
Controversy surrounding the ef~cacy and cost of pur-
ported clot-speci~c agents has led to uncertainty as to
which thrombolytic agent to use. We hypothesized that
temporal trends of thrombolytic use in our emergency
department would likely re_ect the major reports
comparing the ef~cacy of different thrombolytic drugs.
Thus, the speci~c aims of our study were to determine
the impact of a quality assurance program on (1) door-
to-needle time and (2) the choice of thrombolytic
agents in acute myocardial infarction.
Methods
Patient identi~cation
The emergency department records of 349 consecutive
patients receiving thrombolysis for an acute myocar-
dial infarction from September 1989 through March of
1994 were reviewed. All patients included in the study
met criteria for thrombolytic therapy in accord with
written guidelines reported in the literature and used
in our emergency department. These criteria included
the presence of typical ischemic chest pain of at least
30 minutes duration (and up to 12 hours) that was un-
responsive to nitrate therapy and was associated with
at least 1-mm ST segment elevation in two contiguous
leads or new left bundle branch block. Patients with
contraindications to thrombolytic therapy were ex-
cluded from the study. Additional exclusions included
patients who had received the thrombolytic agent for
the index acute myocardial infarction at an outside
hospital, patients who received thrombolysis for a con-
dition other than an acute myocardial infarction, and
patients in whom a thrombolytic agent was ordered
but never received.
Data acquisition
This was a retrospective analysis of a prospective co-
hort study with data on demographic information, vital
signs, myocardial infarction location, choice of throm-
bolytic agent, and hospital mortality analyzed by re-
view of medical records. The door-to-needle time was
calculated from the time of initial triage in the emer-
gency department to the time when the infusion of
streptokinase or t-PA was started. In patients who re-
ceived both streptokinase and t-PA, only the time to
infusion of the ~rst thrombolytic agent was included in
the analysis.
Quality assurance program (Table 1)
The quality assurance program begun in September of
1989 included a monthly review of the emergency de-
partment records of all patients who received throm-
bolytic agents by a clinical nurse specialist and/or at-
tending physician. Issues targeted for review included
whether the documentation was completed by nursing
(e.g., the infusion rate and dose) and physicians (e.g.,
the time the order was written) and an assessment of
the door-to-needle time. The time for drug preparation
was analyzed separately where possible. The records
of patients who had a door-to-needle time exceeding
.1 hour were reviewed in detail by the physician di-
rector of the quality assurance program to identify the
reasons for delay. When appropriate, individuals in-
volved in the care of that patient were contacted to
clarify the possible causes for a delay. Per protocol, the
emergency department staff physician made the deci-
sion to administer thrombolytic therapy without ob-
taining a cardiology consult (unless the patient had
chest pain for more than 12 hours and/or the indica-
tions for thrombolysis were unclear).
A protocol-driven physician–nurse team approach
at the bedside was instituted. Intravenous access was
obtained immediately, and a decision was rendered re-
garding which drug would be used in a patient meet-
ing the criteria for thrombolysis. Updated protocols
that were mounted on the wall of every acute care cu-
bicle were followed in a timely fashion. While the
thrombolytic agent was infusing, additional drugs
were administered, a chest x-ray was obtained, and
blood samples were sent. Thrombolytic agents were
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Table 1. Components of the quality assurance program
1. Immediate ECG
2. Updated protocols posted in every acute care cubicle in the emergency department
3. Team approach (a protocol-driven physician-nurse team)
4. Thrombolytic agent stocked in emergency department
5. Thrombolytic therapy begun in the emergency department (no delays in transfer to the CCU)
6. Thrombolytic therapy begun by emergency department physician, except in ambiguous cases (minimal consulation delays)
7. Review of all thrombolytic-treated MI patients by M.D. or nurse clinical specialists
8. Measure of door-to-needle time
9. Focused review/feedback of patients with door-to-needle times .1 hr
10. Biannual status report
11. Nursing feedback sessions on documentation, thrombolytic drug protocol, drug preparation, etc.
12. House staff teaching conference reviewing current literature/monthly orientation lectures in the emergency department
mandated to be available in the emergency depart-
ment pharmacy at all times.
A biannual status report of the Thrombolysis Qual-
ity Assurance Program was distributed throughout
the hospital (including the hospital administration,
pharmacy, nursing, and the Department of Internal
Medicine). The Department of Nursing held formal
feedback sessions targeting the areas of adequate doc-
umentation, review of the thrombolysis protocol, and
timely preparation and administration of drugs.
Teaching conferences were held for the house staff re-
viewing conclusions from our own database and that
of the thrombolytic literature. Also, a monthly orien-
tation was given in the emergency department for
new house of~cers and a medical grand rounds was
held annually, reviewing the goals of thrombolytic
therapy.
Data analysis
Statistical analysis was done using the BMDP statisti-
cal program [12]. Fisher’s exact tests were used to
compare categorical variables. Student’s t-test was
used to compare independent means of continuous
variables. P values re_ect two-sided tests. Findings
were considered signi~cant when the two-sided P
value was ,0.05. Data are summarized as means with
standard deviations as measures of dispersion. Median
values are reported for variables that were not nor-
mally distributed. For the analysis, patients who re-
ceived thrombolytic therapy during the ~rst 2 years of
implementing the quality assurance effort in
1989–1991 (group A) were compared with patients who
received thrombolytic therapy during the latter 2
years of the study in 1992–1994 (group B), after the
quality assurance program had become an established
component of the emergency department routine.
Results
Of 349 study patients, 78% were men and 22% were
women, with a mean age of 58 6 1 and 67 6 1 years, re-
spectively (P , .001). The mean age increased from 58
6 11 years for group A to 62 6 12 years for group B (P
, .005; Table 2). The location of myocardial infarctions
was similar between group A and B, and consisted of
39% anterior (including anteroseptal and anterolateral
myocardial infarctions), 58% inferior, and 3% lateral
myocardial infarctions. There was no statistically
signi~cant difference in gender or duration of symp-
toms between groups A and B. The overall in-hospital
mortality for patients who received thrombolytic
agents was 3%.
The median door-to-needle time fell signi~cantly
from 46 minutes during 1989–1991 to 36 minutes in
1992–1994 (P , .01). The percentage of patients with
door-to-needle times .60 minutes fell from 35% in
1989–1991 to 16% in 1992–1994, (P , .0001; See Table
3). Over the entire study period, 65% of patients re-
ceived only streptokinase, 32% received t-PA, and 3%
received both. As shown in Figure 1, the proportion of
streptokinase versus t-PA increased from 60% for
group A to 75% for group B (P , .01). Streptokinase
use in anterior myocardial infarctions also increased
from 55% during the 1989–1991 period to 73% during
the 1992–1994 period (P , .05). In addition, the ten-
dency for streptokinase use in inferior myocardial in-
farctions increased from 68% during the 1989–1991 pe-
riod to 80% during the 1992–1994 period (P , .09). For
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Table 2. Demographic information (n 5 349)
Group A                                             Group B
1989–1991 1992–1994 P value
Age
,40 years 10 (5%) 6 (4%) NS
41–64 years 115 (61%) 79 (50%) ,0.05
.65 years 62 (33%) 71 (45%) ,0.02
Mean 6 SD 58 6 11 62 6 12 ,0.005
Gender
Female 47 (25%) 36 (23%) NS
Male 143 (75%) 122 (77%) NS
Duration of symptoms
2 6 hours 58 (31%) 45 (28%) NS
.6 hours 120 (63%) 104 (65%) NS
Type of thrombolytic agent
Streptokinase 112(59%) 113 (72%) ,0.02
t-PA 72(38%) 38 (24%) ,0.007
Streptokinase 6(3%) 5 (3%) NS
1 t-PA
Death during 4(2%) 7 (4%) NS
hospitalization
lateral infarcts, streptokinase and t-PA were used in
similar proportions. The proportion of patients receiv-
ing streptokinase increased signi~cantly over the ~rst
3 years of the study (P , .0001). Analysis of the ~nal 6
months of the study, however, revealed a signi~cant in-
crease in the proportion of patients receiving t-PA, a
clear reversal of prior trends. This trend for increased
utilization of t-PA was seen following the reporting of
the GUSTO trial. Figure 1 illustrates the proportion of
streptokinase versus t-PA use in 6-month intervals
(the period in which the results of ISIS-3 and GUSTO
became available are indicated).
Discussion
We reduced the median time from initial triage to
treatment by 10 minutes (21%) after implementing a
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quality assurance program (see Table 1). Our program
was simple and focused on physician/nurse education
and feedback, as well as a bedside team approach. In
addition, the hospital administration and pharmacy di-
rector were involved. While an absolute reduction of
10 minutes may seem marginal from a clinical view-
point, it is signi~cant in the context of a hospital that
already has a door-to-needle time signi~cantly below
the national average of approximately 90 minutes [10].
The most recent report from the National Registry of
Myocardial Infarction notes a 9-minute reduction in
the median time to treatment (52.5 vs. 43.5 minutes)
when comparing their ~rst enrollment interval in
January 1991 to December 1993, but this registry is ad-
mittedly predominantly composed of tertiary academic
centers.
When data across all 904 hospitals that volunteered
to participate in the National Registry of Myocardial
Infarction were considered, the median time from hos-
pital presentation to treatment was .55 minutes, with
,63% of patients receiving thrombolytic therapy
within 1 hour [13]. This national trend toward de-
creasing the time to treatment is encouraging, given
that our experience with a quality assurance program
in a single center resulted in a greater than 50% re-
duction in the number of patients who received throm-
bolysis .1 hour after presentation. The American
Medical Association and the NIH (National Heart,
Lung, and Blood Institute) and National Heart Attack
Alert Coordinating Committee recommend treating all
acute myocardial infarction patients who are eligible
for thromboytic therapy within 30–60 minutes after
arrival in the emergency department [14,15]. We be-
lieve that opportunities for even greater impact and
clinical bene~t exist in hospitals in which the door-to-
needle time remains 60–90 minutes.
Several studies have examined the causes of delays
in initiating thrombolytic drugs in emergency depart-
ments [4,11]. The two largest studies of in-hospital
time delay [4,11] found several factors that appear to
be important. A policy of transporting the patient to
the coronary care unit prior to initiating thrombolytic
therapy caused delays ranging from 10 to 35 minutes
[4,11]. Signi~cant delays were also related to waiting
for the patient’s private physician to initiate treatment
rather than having the emergency physician alone or
with an on-site cardiology consultant initiate therapy.
Finally, both studies suggested that transporting the
drug from the pharmacy to the emergency department
consumed valuable time and led to unnecessary delays
in preparing and administering the drug. Maynard et
al., in evaluating factors in_uencing the time from hos-
pital presentation to the initiation of thrombolytic
treatment based on data from the National Registry of
Myocardial Infarction, also found that the most impor-
tant factor associated with a shorter time to treatment
was a policy whereby thrombolytic treatment is given
in the emergency department rather than the coro-
nary care unit (47 vs. 73 minutes, P , 0.0001) [13].
Table 3. Impact of quality assurance on thrombolytic therapy
Group A         Group B
1989–1991 1992–1994 P Value
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ED 5 emergency department.
Figure 1. Potential In_uence of megatrials on thrombolytic
choice. The proportion of patients meeting acute myocardial
infarction criteria receiving SK (streptokinase) versus t-PA
(tissue plasminogen activator) in 6-month intervals. * ISIS-3
results reported/disseminated to physician staff. 1 GUSTO I
results reported/disseminated to physician staff.
While it is agreed that the most important determi-
nant of maximal thrombolytic bene~t is the appropri-
ate early administration of the drug, there have been
relatively few studies that address how to reduce the
door-to-needle time through an intervention. The
Western Washington trials are the largest to date to
examine the effect of a quality assurance program on
the utilization of thrombolytic agents [8]. The authors
compared the time to treatment during 1983–1986 to
the time to treatment during 1987–1988 and demon-
strated a reduction from an average of 97 minutes to
52 minutes with a program that streamlined the drug-
delivery protocol and educated the staff in time-saving
measures.
In a study of 24 patients in the emergency depart-
ment at Hennepin County Medical Center, an average
time from triage to treatment of 67 minutes was docu-
mented. By streamlining procedures for thrombolytic
administration, the time to treatment fell to a mean of
30 minutes (range 17–44) in the nine subsequent pa-
tients studied [4]. Several community hospitals have
also demonstrated a reduction in the time to treatment
after a quality assurance program [16]. One recent re-
port examined the impact of a quality assurance pro-
gram in a community hospital in California that in-
cluded physician and nurse education, feedback
sessions, a mandate that treatment decisions be made
by the emergency department physicians, and a team
approach to bedside care [16]. The mean time from ar-
rival in the emergency department to thrombolytic
therapy was 63 minutes in 1988 and fell to 38 minutes by
1990 (P , 0.0002). Through a similar quality assurance
program (see Table 1), we were able to reduce the time
from initial triage to treatment by 10 minutes (,21%).
One might argue that prehospital thrombolytic
treatment is the most ef~cient method of improving
the timeliness of treatment for myocardial infarction,
particularly in light of reports of in-hospital delays av-
eraging 45–90 minutes, as noted earlier [4]. In support
of this concept, the MITI trial demonstrated a time
savings of 30 minutes with administration of prehospi-
tal thrombolysis [17]. However, in the MITI trial, only
5% of patients with chest pain were candidates for pre-
hospital thrombolysis and hospital arrival was delayed
by at least 15 minutes. Also, it is known that for hospi-
tals with active emergency departments, less than 50%
of patients with acute myocardial infarctions arrive by
ambulance [4]. Recently, the American College of
Emergency Physicians elected not to endorse the rou-
tine prehospital use of thrombolytic agents until fur-
ther research proves its bene~t. In particular, the col-
lege suggested the prehospital treatment was no
substitute for unnecessary delays incurred within the
emergency department [9].
It is unclear whether recommendations for reduc-
ing the door-to-needle time to less than 30 minutes are
realistic [18]. As determined by a Medline review,
there has not been a study in the United States that
has achieved a mean time to treatment under 30 min-
utes for in-hospital evaluation and therapy. Cannon et
al. mention a study in which the door-to-needle time
was reduced from 76 minutes to 48 minutes after im-
plementation of an acute myocardial infarction proto-
col; in the last 3 months of the study, a 29-minute av-
erage door-to-needle time trend was statistically
signi~cant [20]. Two studies outside the United States,
one in New Zealand and the other in Scotland, were
able to achieve a time to thrombolysis of less than or
equal to 40 minutes. Porter et al. in New Zealand,
through a staff education program to fast track the
management of patients eligible for thrombolysis,
demonstrated a decrease in the median door-to-needle
time from 59 to 40 minutes [19]. Currie et al. in
Scotland, through a similar audit that included staff
education regarding thrombolysis guidelines, de-
creased the time to thrombolysis from a median of 55
minutes to 38 minutes [21]. In the United States, the
series from Hennepin County [8] is the only study that
was able to achieve a mean 30-minute door-to-needle
time and that was only in nine patients. Our study is
one of the few to achieve a door-to-needle time ,40
minutes. As mentioned earlier, Cummings, using a sim-
ilar quality assurance effort in a nonacademic commu-
nity hospital was able to reduce the mean time from
emergency department arrival to thrombolytic ther-
apy from 63 to 38 minutes (P , .002) [16]. In a com-
munity hospital setting with a university af~liation,
Anderson et al. implemented a quality improvement
effort and decreased the mean time from arrival to
thrombolytics from 93 6 66 to 53.5 6 43 minutes (P ,
.001) [22]. In a retrospective study using historical con-
trols in a nonacademic setting, Krall and Reese noted
after the implementation of a continuous quality im-
provement intervention, which included chart review,
intensive systems analysis, and staff feedback, there
was a reduction in the triage to thrombolytic time from
72 6 25 to 40 6 22 minutes [23].
Trends in usage of thrombolytic agents
This study suggests that conformity to megatrials may
be a function of both physician education and immedi-
ate feedback regarding current institutional practice.
Given the recent abstract in Circulation [24] reporting
that physician practice often does not conform to pub-
lished guidelines, or even the compelling evidence of
the esteemed megatrial, this result is particulary in-
teresting. Early trials of thrombolytic therapy, such as
the European Cooperative study, suggested that t-PA
resulted in greater patency of the infarct-related
artery (IRA) at 90 minutes [25]. However, several sub-
sequent megatrials, such as GISSI-2 (n 5 20,891) [26]
followed by ISIS-3 (n 5 39,713) [27], demonstrated
that no additional survival bene~t was conferred by 
t-PA when compared with the less expensive agent,
streptokinase.
In the spring of 1993, the results of the GUSTO trial
[28] became available, demonstrating a mortality re-
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duction of 14% when accelerated t-PA was used rather
than streptokinase. Although the ISIS-3 trial (demon-
strating comparable ef~cacy among streptokinase,
anistreplase (APSAC), and t-PA) was published in the
Lancet in March 1992, preliminary results were known
and discussed in conferences with our house staff by
December 1991 and were part of our ongoing quality
assurance efforts. Using the method of comparing the
patients treated during the ~rst 2 years of implement-
ing the quality assurance effort to the latter 2 years of
the established program, our data happened to coin-
cide with the advent of information regarding ISIS-3,
allowing for a pre- and post-megatrial comparison.
Similarly, preliminary results of the GUSTO trial, pub-
lished in September of 1993, were available in the
spring of 1993 and were shared with our myocardial in-
farction management teams.
In our study, the use of streptokinase increased
from 1989–1991 to 1992–1994 (60–75%), after ISIS-3
was published (P , .01). When the 4-year period is di-
vided into 6-month intervals, there was an increase in
the use of streptokinase, trending toward statistical
signi~cance after the preliminary results of ISIS-3 be-
came available in December 1991. This trend continued
until the time interval in the spring of 1993, when the
results of GUSTO become available and the use of 
t-PA increased (and that of streptokinase decreased).
These data support the broadly held belief that large
multicenter controlled trials have an almost immediate
impact on practice behavior, perhaps particularly in
large, urban, teaching institutions such as ours. At a
time when cost effectiveness is an increasingly impor-
tant consideration, understanding how megatrials im-
pact physician practices has important implications for
overall healthcare costs.
Conclusions
Thrombolytic therapy has dramatically altered the
prognosis of patients with acute myocardial infarction.
However, this survival bene~t is dependent on the
time interval from the inception of ischemia to the de-
livery of the thrombolytic agent. Clearly, a substantial
component of the delay to treatment is attributable to
the patient’s delay in seeking medical attention. Thus
intensive patient education has an important role in
optimizing the bene~ts of thrombolytic agents.
However, it has been demonstrated that the in-hospi-
tal delay is often greater than the interval from the
onset of symptoms to arrival in the emergency depart-
ment [4]. We believe that quality assurance programs
in the emergency department can signi~cantly de-
crease the critical time to thrombolytic therapy. This
study of the effect of a relatively simple quality assur-
ance program on the door-to-needle time in the emer-
gency department of a major teaching hospital could
serve as a model for others trying to achieve reduc-
tions in the time to treatment of appropriate patients.
Finally, our data add further evidence that reports
of megatrials can rapidly and signi~cantly in_uence
clinical practice. This has profound implications for the
costs of care for hospitals and underscores industry’s
preoccupation with megatrials.
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